Suzhou Shengdi Biopharmaceutical

Suzhou Shengdi Biopharmaceutical is a leading biotechnology company and a core subsidiary of Jiangsu Hengrui Pharmaceuticals, located in the Suzhou Industrial Park. The company focuses on the research, development, and large-scale manufacturing of innovative biologics, particularly in the fields of oncology and autoimmune diseases. Its flagship product, Camrelizumab (a PD-1 inhibitor), has received multiple approvals in China for various cancer indications. Suzhou Shengdi operates state-of-the-art GMP manufacturing facilities and serves as a critical hub for Hengrui's global biologics strategy. The company's pipeline includes a diverse range of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.